v3.26.3
Liability Related to the Revenue Participation Right (Details) - Royalty Pharma - Royalty Agreement - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2026
Sep. 30, 2026
Sep. 30, 2026
Dec. 31, 2025
Other Commitments [Line Items]        
Authorized funding       $ 275.0
Royalty rate       9.25%
Proceeds received $ 200.0      
Additional payment       $ 75.0
Initial investment proceeds multiple, maximum       3.0
Initial investment proceeds multiple, minimum       2.5
Transaction costs $ 0.4      
Annual interest rate   12.00% 12.00%  
Interest expense   $ 6.1 $ 12.1  
Payments for royalties   $ 0.3 $ 0.3